Vfend Powder, For Suspension
NDC Package 0049-3160-44

11-digit billing NDC: 00049316044 · Billing unit: ML · 75 ML per package

Package Information

Vfend (voriconazole) powders is •VFEND is contraindicated in patients with known hypersensitivity to voriconazole or its excipients [see Warnings and Precautions (5.5) and Adverse Reactions (6.1, 6.2)]. This formulation utilizes a powder, for suspension delivery system. Marketed by Roerig, this product is identified by NDC 0049-3160 and is authorized under FDA application NDA021630.

Identification & Billing

NDC Package Code
0049-3160-44
Package Description
1 BOTTLE in 1 CARTON / 75 mL in 1 BOTTLE
Product Code
11-Digit Billing Format
00049316044
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
Units Per Package
75 ML
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Vfend
Non-Proprietary Name
Voriconazole
Substance Name
Voriconazole
Dosage Form
Powder, For Suspension - An intimate mixture of dry, finely divided drugs and/or chemicals, which, upon the addition of suitable vehicles, yields a suspension (a liquid preparation containing the solid particles dispersed in the liquid vehicle).
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
•VFEND is contraindicated in patients with known hypersensitivity to voriconazole or its excipients [see Warnings and Precautions (5.5) and Adverse Reactions (6.1, 6.2)]. There is no information regarding cross-sensitivity between VFEND and other azole antifungal agents. Refer to the prescribing information for other azole antifungal agents.•Concomittant use of VFEND with the interacting drugs described and listed below in this section are a guide and not considered a comprehensive list of all possible drugs that may be contraindicated with VFEND.1.Concomitant use of VFEND is contraindicated with drugs that are highly dependent on CYP3A4 for metabolism, and for which elevated plasma concentrations are associated with serious and/or life-threatening reactions [see Drug Interactions (7)]:•Eplerenone•Ergot alkaloids (e.g., ergotamine, dihydroergotamine)•Finerenone•Ivabradine•Lurasidone•Naloxegol•Pimozide•Quinidine•Rifabutin [see Clinical Pharmacology (12.3)]•Sirolimus [see Clinical Pharmacology (12.3)]•Tolvaptan•Venetoclax: Coadministration at initiation and during the ramp-up phase is contraindicated in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) due to the potential for increased risk of tumor lysis syndrome [see Drug Interactions (7)].•Voclosporin2.Concomitant use of VFEND is contraindicated with drugs and herbal products that induce CYP2C19, CYP2C9, and/or CYP3A4 and for which significantly reduced voriconazole plasma concentrations may be associated with loss of efficacy [see Drug Interactions (7)]:•Carbamazepine•EfavirenzConcomitant use with efavirenz dosages of 400 mg every 24 hours or higher is contraindicated [see Clinical Pharmacology (12.3)].•Long-acting barbiturates•Rifabutin•Rifampin•RitonavirConcomitant use with high-dose ritonavir (400 mg every 12 hours) is contraindicated. Concomitant use with low-dose ritonavir (100 mg every 12 hours) should be avoided, unless an assessment of the benefit/risk to the patient justifies the use of VFEND [see Clinical Pharmacology (12.3)].•St. John’s Wort [see Clinical Pharmacology (12.3)]

Regulatory & Marketing

Labeler Name
Roerig
Product Type
Human Prescription Drug
FDA Application #
NDA021630
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
03-28-2003
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0049-3160-44 identifies a specific commercial package of 1 bottle in 1 carton / 75 ml in 1 bottle of Vfend, a human prescription drug labeled by Roerig. This product is billed per "ML" milliliter and contains an estimated amount of 75 billable units per package. This powder, for suspension is formulated for oral use and contains voriconazole as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Roerig on March 28, 2003. The current certification is valid through December 31, 2027.

How is this Roerig product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00049316044. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 75 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0049-3160-44
11-Digit CMS (5-4-2)
00049-3160-44

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.